146 related articles for article (PubMed ID: 28777460)
21. Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-δ Inhibitor CAL-101.
Riyahi N; Safaroghli-Azar A; Sheikh-Zeineddini N; Sayyadi M; Bashash D
Cancer Invest; 2019; 37(7):311-324. PubMed ID: 31412710
[TBL] [Abstract][Full Text] [Related]
22. C‑Myc inhibitor 10058‑F4 increases the efficacy of dexamethasone on acute lymphoblastic leukaemia cells.
Lv M; Wang Y; Wu W; Yang S; Zhu H; Hu B; Chen Y; Shi C; Zhang Y; Mu Q; Ouyang G
Mol Med Rep; 2018 Jul; 18(1):421-428. PubMed ID: 29749488
[TBL] [Abstract][Full Text] [Related]
23. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.
Shi Y; Beckett MC; Blair HJ; Tirtakusuma R; Nakjang S; Enshaei A; Halsey C; Vormoor J; Heidenreich O; Krippner-Heidenreich A; van Delft FW
Haematologica; 2021 Apr; 106(4):1056-1066. PubMed ID: 32139432
[TBL] [Abstract][Full Text] [Related]
24. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.
Vangapandu HV; Jain N; Gandhi V
Expert Opin Investig Drugs; 2017 May; 26(5):625-632. PubMed ID: 28388280
[TBL] [Abstract][Full Text] [Related]
25. Suppression of c-Myc using 10058-F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells.
Sheikh-Zeineddini N; Bashash D; Safaroghli-Azar A; Riyahi N; Shabestari RM; Janzamin E; Safa M
J Cell Biochem; 2019 Aug; 120(8):14004-14016. PubMed ID: 30957273
[TBL] [Abstract][Full Text] [Related]
26. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML
Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265
[TBL] [Abstract][Full Text] [Related]
27. TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway.
Zhao Q; Zhao S; Li J; Zhang H; Qian C; Wang H; Liu J; Zhao Y
Biomed Pharmacother; 2019 Jan; 109():1640-1649. PubMed ID: 30551418
[TBL] [Abstract][Full Text] [Related]
28. Glucocorticoids paradoxically promote steroid resistance in B cell acute lymphoblastic leukemia through CXCR4/PLC signaling.
Abdoul-Azize S; Hami R; Riou G; Derambure C; Charbonnier C; Vannier JP; Guzman ML; Schneider P; Boyer O
Nat Commun; 2024 May; 15(1):4557. PubMed ID: 38811530
[TBL] [Abstract][Full Text] [Related]
29. Gene Expression and Resistance to Glucocorticoid-Induced Apoptosis in Acute Lymphoblastic Leukemia: A Brief Review and Update.
Lambrou GI; Adamaki M; Hatziagapiou K; Vlahopoulos S
Curr Drug Res Rev; 2020; 12(2):131-149. PubMed ID: 32077838
[TBL] [Abstract][Full Text] [Related]
30. Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.
Ge Z; Song C; Ding Y; Tan BH; Desai D; Sharma A; Gowda R; Yue F; Huang S; Spiegelman V; Payne JL; Reeves ME; Iyer S; Dhanyamraju PK; Imamura Y; Bogush D; Bamme Y; Yang Y; Soliman M; Kane S; Dovat E; Schramm J; Hu T; McGrath M; Chroneos ZC; Payne KJ; Gowda C; Dovat S
Leukemia; 2021 May; 35(5):1267-1278. PubMed ID: 33531656
[TBL] [Abstract][Full Text] [Related]
31. A New Indole Derivative, LWX-473, Overcomes Glucocorticoid Resistance in Jurkat Cells by Activating Mediators of Apoptosis.
Song J; Yang K; Gajendran B; Varier KM; Li W; Liu Q; Rao Q; Hang Y; Shen X; Liu S; Huang L; Xu M; Li Y
Front Biosci (Landmark Ed); 2024 Apr; 29(4):163. PubMed ID: 38682179
[TBL] [Abstract][Full Text] [Related]
32. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
Horwitz SM; Koch R; Porcu P; Oki Y; Moskowitz A; Perez M; Myskowski P; Officer A; Jaffe JD; Morrow SN; Allen K; Douglas M; Stern H; Sweeney J; Kelly P; Kelly V; Aster JC; Weaver D; Foss FM; Weinstock DM
Blood; 2018 Feb; 131(8):888-898. PubMed ID: 29233821
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of the dual-luciferase report assay for predicting response to glucocorticoid in children with acute lymphoblastic leukemia.
Wang X; Chen P; Sun Y; Chen Y; Mao M; Jiang T; Ouyang J
Clin Transl Oncol; 2017 Oct; 19(10):1241-1246. PubMed ID: 28444640
[TBL] [Abstract][Full Text] [Related]
34. Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance via N-linked glycosylation inhibition under normoxia.
Gu L; Yi Z; Zhang Y; Ma Z; Zhu Y; Gao J
Oncotarget; 2017 May; 8(19):30978-30991. PubMed ID: 28415682
[TBL] [Abstract][Full Text] [Related]
35. Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL.
Levinson AL; Tjoa K; Huang B; Meyer LK; Kim MO; Brady SW; Zhang J; Shannon K; Wandler AM
Blood Adv; 2023 Jul; 7(14):3479-3484. PubMed ID: 36897249
[TBL] [Abstract][Full Text] [Related]
36. Targeting autophagy as a therapeutic strategy in pediatric acute lymphoblastic leukemia.
Bwanika HC; Leo IR; Struyf N; Talanti A; Aswad L; Konnur A; Björklund AC; Heyman M; Rassidakis G; Erkers T; Seashore-Ludlow B; Jafari R; Pokrovskaja Tamm K
Sci Rep; 2024 Feb; 14(1):4000. PubMed ID: 38369625
[TBL] [Abstract][Full Text] [Related]
37. Role of microRNAs in glucocorticoid‑resistant B‑cell precursor acute lymphoblastic leukemia.
Sakurai N; Komada Y; Hanaki R; Morimoto M; Ito T; Nakato D; Hirayama M
Oncol Rep; 2019 Aug; 42(2):708-716. PubMed ID: 31233193
[TBL] [Abstract][Full Text] [Related]
38. ESRRB regulates glucocorticoid gene expression in mice and patients with acute lymphoblastic leukemia.
Gallagher KM; Roderick JE; Tan SH; Tan TK; Murphy L; Yu J; Li R; O'Connor KW; Zhu J; Green MR; Sanda T; Kelliher MA
Blood Adv; 2020 Jul; 4(13):3154-3168. PubMed ID: 32658986
[TBL] [Abstract][Full Text] [Related]
39. Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression.
Toscan CE; Jing D; Mayoh C; Lock RB
Br J Cancer; 2020 Jun; 122(12):1769-1781. PubMed ID: 32242100
[TBL] [Abstract][Full Text] [Related]
40. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis.
Carlos JAEG; Lima K; Costa-Lotufo LV; Leitão A; Machado-Neto JA
Invest New Drugs; 2021 Aug; 39(4):1139-1149. PubMed ID: 33475938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
